PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.76%
EBIT growth 10-15% – Solid. Seth Klarman would see if this level of profit expansion is sustainable across cycles.
10.76%
Operating income growth 10-15% – Solid. Seth Klarman would look at whether overhead costs remain controlled for long-term stability.
11.35%
Net income growth 10-15% – Solid. Seth Klarman would verify if cost control or pricing is driving consistent profit expansions.
31.03%
EPS growth above 25% – Exceptional. Warren Buffett would double-check that it’s not solely driven by aggressive buybacks rather than real profit increases.
31.72%
Diluted EPS growth above 25% – Impressive performance. Warren Buffett would confirm if major buybacks or real profit improvements drive these gains.
29.31%
Share count growth exceeding +3% – Notable dilution. Philip Fisher would want justification for new share issuance or acquisitions.
29.44%
Diluted share count growth above 3% – Noticeable dilution. Philip Fisher would question the rationale for issuing more stock or options.
No Data
No Data available this quarter, please select a different quarter.
2.31%
OCF growth 0-5% – Minimal gain. Howard Marks would be cautious about the company’s ability to fund large projects or dividends.
3.06%
FCF growth 0-5% – Slight improvement. Howard Marks would be cautious about cyclical or temporary factors limiting free cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-254578.19%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
64.50%
5Y OCF/share CAGR above 15% – Very robust mid-term cash expansion. Warren Buffett would check if reinvestment fosters sustainable growth.
73.57%
3Y OCF/share CAGR above 15% – Rapid short-term expansion. Warren Buffett would see if this stems from genuine operational improvements vs. working-capital swings.
-9976.84%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
-124.34%
A negative 5Y net income/share CAGR reveals a mid-term deterioration in bottom-line earnings. Benjamin Graham would be cautious unless a credible turnaround is visible.
76.73%
3Y net income/share CAGR above 15% – Rapid short-term profit growth. Benjamin Graham would verify if it’s driven by core revenue or temporary cost reductions.
1493.31%
10Y equity/share CAGR above 12% – Excellent long-term book value compounding. Warren Buffett would see if consistent profits plus moderate payouts drive this growth.
-38.28%
Negative 5Y equity/share CAGR suggests net worth destruction. Benjamin Graham would see if failing profitability or large payouts cause it.
-74.77%
Negative 3Y equity/share CAGR means a near-term drop in book value. Benjamin Graham would be cautious unless restructured operations promise a future rebound.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.33%
Asset growth above 20% – Rapid expansion. Warren Buffett checks if returns justify this investment and if debt finances it unsafely.
127.26%
Book value/share growth above 12% annually – Strong sign of compounding. Warren Buffett verifies if profits or buybacks mainly drive it.
-9.95%
A negative growth rate in debt means deleveraging, often positive for conservative investors. Benjamin Graham confirms it doesn’t restrict needed investments.
-7.53%
A big drop in R&D might boost near-term earnings but risk starving the pipeline. Benjamin Graham sees if the firm is refocusing or if future growth suffers.
-21.01%
Shrinking SG&A can raise profits short term, but might risk cutting key growth drivers. Benjamin Graham sees if this is sustainable.